On the heels of his study, Dr. James Berenson an oncologist specializing in multiple myeloma —announced his latest findings and … Article
Archive | Press Releases RSS feed for this section
Cancer Patients Join Oncologist Who Releases Results of COVID-19 Vaccine/Cancer Study
IMBCR & Emory University’s Big Discovery!!!
February 7, 2022
Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response against SARS-CoV-2 is unknown. Thus, … Article
James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center
February 6, 2022
New name, logo, and business unit alignment introduced as part of an extensive rebranding initiative
LOS ANGELES, Nov. 11, … Article
James R. Berenson, MD
- President & CEO, Institute for Myeloma & Bone Cancer Research (IMBCR)
- President & Medical Director. Berenson Cancer Center (Berensoncancercenter)
- Founder & President, ONCOtherapeutics
- Founder & Principal, ONCOtracker
-
Cancer Patients Join Oncologist Who Releases Results of COVID-19 Vaccine/Cancer Study
-
IMBCR & Emory University’s Big Discovery!!!
-
James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center
- What Is Multiple Myeloma?
-
Video Updates
- Kyphon® Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients
- The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
- Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting
- Understanding Myeloma News About Secondary Cancers and Clotting
-
Dedication of “Determination”
February 8, 2022
0 Comments